Menu
BWXT Medical has a strong network of industry and strategic collaborators to achieve our high level of innovation.
In 2018, BWXT acquired Sotera Health’s Nordion Medical Isotopes division to enable the development and delivery of a ground-breaking technology. BWXT’s medical business – BWXT Medical – is now poised to make a significant, positive impact on the supply reliability of the North American nuclear medicine market.
This acquisition enabled access to long-standing relationships that have led to new and exciting collaborations.
Co-located with TRIUMF on the University of British Columbia campus in Vancouver, we collaborate and share expertise to bring medical radioisotopes from concept to routine commercial delivery.
We are working with Laurentis Energy Partners (Laurentis) and Ontario Power Generation (OPG) toward the potential production and shipment of medical isotopes across the globe. At OPG’s Darlington Nuclear Generating Station, we have installed our proprietary Target Delivery System, co-developed with Laurentis, which allows the production of medical radioisotopes alongside the generation of zero-carbon electricity for the province of Ontario.
Based on more than three decades of collaboration, we work with the University of Missouri Research Reactor (MURR) to bring medical radioisotopes from concept to routine commercial delivery.
Since 2022, we have supplied Bayer AG with high purity Actinium-225. We are pleased to support the work of Bayer, a global leader in the rapidly evolving field of targeted radionuclide therapies.
We are collaborating with Boston Scientific on a long-term, mutually exclusive, agreement to manufacture TheraSphere™, an innovative therapy that is changing the lives of liver cancer patients, and their families, around the world.
At BWXT Medical, we are committed to collaborating with industry leaders and innovators to develop cutting-edge solutions in nuclear medicine. By working together, we can drive progress and revolutionize the way we approach healthcare. Join us in our mission to make the world a healthier place by collaborating with us today.
We are supplying Fusion Pharmaceuticals with our innovative generator technology for the supply of Ac-225, which is being used in their clinical research into cancer-fighting drugs.
We supply Bracco Diagnostics Inc. with Strontium-82. This critical isotope is fundamental in the manufacturing of rubidium-82 generators used in important cardiac PET imaging procedures.
We are collaborating with iThemba LABS (Laboratory for Accelerator-Based Sciences) to provide medical radioisotopes from concept to routine commercial delivery.
